Optimizing Care for patients with Muscle Invasive Bladder Cancer (MIBC) Grant

Optimizing Care for patients with Muscle Invasive Bladder Cancer (MIBC) Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: C $50,000 - C $300,000
Last Updated: January 12, 2026

Summary

Overview

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Optimizing Care for patients with Muscle Invasive Bladder Cancer (MIBC) Overview This competitive grant offering seeks to optimize the care of patients with muscle invasive bladder cancer (MIBC). Project Types and Area of Interest This RFP seeks solutions for the optimization of care of patients with muscle invasive bladder cancer (MIBC). Ideally, these projects will address important care gaps to facilitate the integration of perioperative treatments, have shortterm impact, have the ability to benefit community clinical practices, and/or involve multi-institution collaborations. This may include, but is not limited to solutions for: Reducing waiting times in the MIBC patient journey Developing clear and efficient referral pathways in patients diagnosed with MIBCImplementing flexible multidisciplinary care models in low-resource settings, either within a single institution or through collaborative multiinstitutional partnershipsOptimizing patients before cystectomy (health, lifestyle) Establishing non-MD-led adverse events (AE) management clinics (the physician is involved, but the clinic is managed by another healthcare professional)

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.